As shown in Fig. 1a, over 50% of the 19 AML patients expressed moderate levels of DR4, DR5, DcR1, or DcR2, whereas 4 out of 19 AML patients expressed relatively high levels of CAR (>5% positive cells) and 1 out of 19 patients expressed relatively high levels of integrin αvβ5 (>5% positive cells) (Fig. 1a and Supplementary Table S1). The gene discussed is TNFRSF10B; the disease is acute myeloid leukemia.